Core Insights - JD Health and Love Health signed a strategic cooperation agreement for 2026, aiming to enhance collaboration in the healthcare supply chain, digital marketing innovation, user service experience, and project incubation in the sexual health industry [1][3] Group 1: Strategic Partnership - The partnership focuses on "co-building high growth" by leveraging resource advantages to drive the sexual health industry towards professionalism and digitization [1] - JD Health has become the launch platform for new strategic products from Love Health, indicating a strong collaborative relationship [3] Group 2: Marketing and Product Performance - Since 2025, both companies have engaged in deep marketing cooperation, utilizing a "breakthrough products + scenario penetration" model to stimulate consumer enthusiasm and expand brand presence [3] - The Durex brand, under Love Health, launched the Durex Super Thin 003 delay condom on JD's platform, achieving over 10 million sales within a month, setting an industry benchmark [3] - In the lubricant category, Durex leads with a comprehensive medical product line, with hyaluronic acid lubricants seeing over 20% year-on-year growth and female pleasure liquids growing over 30%, meeting market demand for safe and comfortable health products [3] - Durex's delay spray and wet wipes also demonstrated strong market competitiveness, with a 95% year-on-year increase in sales, gaining consumer favor [3] Group 3: Future Directions - The signing of the strategic cooperation agreement marks a significant milestone for both companies, with plans to continue driving product innovation and exploring the integration of smart technology in health and lifestyle [3]

Core Insights - The silver-haired demographic is emerging as a significant force in China's health economy by 2025, shifting from a focus on basic needs to a desire for enhanced quality of life and smart consumption [1][2] Group 1: Changing Consumption Patterns - Over 60% of the new silver-haired group have raised their quality of life expectations post-retirement, moving from a focus on low-cost practicality to a preference for quality and smart solutions [1] - The trend of purchasing health-related products online is growing, with e-commerce platforms becoming key channels for the silver-haired population to buy various medications and health products [2][3] Group 2: Increased Demand for Professional Health Services - There is a rising demand for professional health services among the elderly, as evidenced by cases of individuals being misled in online purchases, highlighting the need for transparent and reliable health guidance [6][7] - The introduction of AI doctors, pharmacists, and nutritionists has significantly lowered the barriers for elderly users to seek health consultations, with a notable increase in user engagement during late hours [9][10] Group 3: Technological Integration in Health Management - The integration of AI and smart health products is transforming elderly care, with products like dynamic blood glucose monitors showing significant sales growth, indicating a shift towards proactive health management [10][12] - Companies like JD Health are evolving from mere product sales to comprehensive health management solutions, aiming to serve the deep health management needs of the silver-haired population [12][13]

Core Insights - The conference focused on children's health, emphasizing the collaboration between medical, pharmaceutical, insurance, educational, and family sectors to address industry challenges [3][6] - The establishment of the JD Health Pediatric Ecosystem Alliance aims to enhance the accessibility of quality zinc supplementation products for children [8][9] Group 1: Conference Highlights - The conference featured discussions on key topics such as respiratory diseases, epilepsy treatment, mental health, and infant growth by leading medical experts [3] - Experts highlighted the importance of a balanced approach to children's physical and mental health, aligning with the brand philosophy of focusing on precise nutrition for children's growth [3] Group 2: Company Initiatives - Guangdong He Yi Yun Kang Pharmaceutical's representative introduced the development path and ecological collaboration strategy of the zinc supplement brand, Ju Ke Sheng, which focuses on professional, safe, and precise nutrition [5] - Ju Ke Sheng aims to enhance brand credibility through a knowledge matrix of medical experts and KFS marketing strategies, successfully reaching a wider audience with scientific zinc supplementation knowledge [6] Group 3: Industry Context - The children's medication and nutrition supplement sector in China faces numerous challenges, prompting JD Health to adopt a comprehensive approach covering nine core medication categories and over 460 pediatric products [8] - The JD Health Pediatric Ecosystem Alliance will facilitate resource sharing and complementarity among industry players, enhancing the product matrix and professional service capabilities [8] Group 4: Future Directions - Ju Ke Sheng plans to maintain its focus on children's zinc supplementation, optimizing product development and service systems based on clinical needs and user experiences [9] - The brand will leverage the resources of the JD Health Pediatric Ecosystem Alliance to promote scientific, safe, and convenient zinc supplementation services for families [9]

Core Insights - JD Health and H&H Group have signed a strategic cooperation agreement aiming for a combined business target of 10 billion yuan over the next three years, marking an upgrade to a comprehensive and deep strategic partnership after ten years of close collaboration [1][2] Group 1: Partnership Details - The partnership will focus on enhancing supply chain efficiency, user health management, and data-driven innovation, leveraging JD Health's integrated sales and supply chain capabilities to effectively reach target users for H&H Group's diverse nutrition product lines [2] - H&H Group's CEO, Li Fengting, emphasized the importance of JD Health as a key partner in the Chinese market, aiming to integrate global quality nutrition resources with JD Health's digital technology and user insights [2] Group 2: Market Context - The collaboration comes amid a backdrop of continuous upgrades in health consumption, aiming to drive the health industry towards a more professional, systematic, and personalized development phase, providing richer health products and more convenient shopping experiences for Chinese families [3]

针对黄褐斑易复发的痛点，孚立美®在8周标准治疗后可采用梯度维持方案：第9周至12周隔天一 次，第13周至16周每周两次，第17周至20周每周一次，有效降低复发风险，让祛斑效果更持久。 目前，孚立美®已在京东健康正式开启独家预约，用户可通过京东APP搜索"孚立美"，在线咨询专 业医师后完成处方开具与购买，足不出户即可获得规范治疗方案。针对首次预约用户，还可享受医师一 对一用药指导、全程疗效跟踪等专属服务，让科学祛斑更省心、更安心。 （编辑 郭之宸） 本报讯 （记者梁傲男）12月25日，孚诺医药旗下新药孚立美®氟轻松氢醌维A酸乳膏在京东健康开 启独家预约，为中重度黄褐斑患者带来科学祛斑新方案。用户通过京东APP搜索"孚立美"即可预约。 黄褐斑的发病与遗传、日光照射、激素变化密切相关，尤其多见于30-39岁育龄女性、妊娠后女 性、长期日晒或熬夜的职场人群。孚立美®适用于在防晒措施下，对面部中、重度黄褐斑的短期治疗， 无论是活动期的基础治疗，还是稳定期联合光电治疗的辅助方案，均被《中国黄褐斑诊疗专家共识 （2021版）》推荐为一线用药。 作为国内首款获批的Kligman配方制剂，孚立美®配方包含0.01%氟轻松、4% ...

本报讯(记者梁傲男)12月25日，孚诺医药旗下新药孚立美氟轻松氢醌维A酸乳膏在京东健康开启独家预 约，为中重度黄褐斑患者带来科学祛斑新方案。用户通过京东APP搜索"孚立美"即可预约。 黄褐斑的发病与遗传、日光照射、激素变化密切相关，尤其多见于30-39岁育龄女性、妊娠后女性、长 期日晒或熬夜的职场人群。孚立美适用于在防晒措施下，对面部中、重度黄褐斑的短期治疗，无论是活 动期的基础治疗，还是稳定期联合光电（300691）治疗的辅助方案，均被《中国黄褐斑诊疗专家共识 (2021版)》推荐为一线用药。 作为国内首款获批的Kligman配方制剂，孚立美配方包含0.01%氟轻松、4%氢醌、0.05%维A酸三种精准 配比的活性成分，三者协同发力：氢醌强效阻断黑素生成，维A酸加速色素脱落并促进药物渗透，氟轻 松则减轻皮肤刺激、稳定皮肤状态。 针对黄褐斑易复发的痛点，孚立美在8周标准治疗后可采用梯度维持方案：第9周至12周隔天一次，第13 周至16周每周两次，第17周至20周每周一次，有效降低复发风险，让祛斑效果更持久。 目前，孚立美已在京东健康正式开启独家预约，用户可通过京东APP搜索"孚立美"，在线咨询专业医师 后完成处 ...

12月25日，孚诺医药旗下新药孚立美®氟轻松氢醌维A酸乳膏在京东健康开启独家预约，为中重度黄褐 斑患者带来科学祛斑新方案。用户通过京东APP搜索"孚立美"即可预约。 目前，孚立美®已在京东健康正式开启独家预约，用户可通过京东APP搜索"孚立美"，在线咨询专业医 师后完成处方开具与购买，足不出户即可获得规范治疗方案。针对首次预约用户，还可享受医师一对一 用药指导、全程疗效跟踪等专属服务，让科学祛斑更省心、更安心。 作为国内首款获批的Kligman配方制剂，孚立美®配方包含0.01%氟轻松、4%氢醌、0.05%维A酸三种精 准配比的活性成分，三者协同发力：氢醌强效阻断黑素生成，维A酸加速色素脱落并促进药物渗透，氟 轻松则减轻皮肤刺激、稳定皮肤状态。 临床数据显示，使用孚立美®治疗4周即可看到明显淡斑效果，8周为一个标准疗程，整体有效率高达 68.57%，部分患者治疗12个月后完全或接近清除率可达94%。更值得关注的是，其疗效与原研产品等 效，且不良反应发生率更低，安全性更优。 针对黄褐斑易复发的痛点，孚立美®在8周标准治疗后可采用梯度维持方案：第9-12周隔天一次，第13- 16周每周两次，第17-20周每周一次 ...

Core Viewpoint - JD Health and H&H Group have signed a strategic cooperation agreement to deepen their collaboration over the next three years, aiming for a combined business target of 10 billion [2][7]. Group 1: Partnership Development - The partnership marks an upgrade to a comprehensive and in-depth strategic relationship after ten years of close cooperation [2][7]. - Since their first collaboration in 2015, JD Health and H&H Group have worked together for a decade [4][9]. Group 2: Product and Marketing Initiatives - In 2025, H&H Group's key products, including Swisse high-purity fish oil and Biostime super probiotics, will be launched exclusively on JD Health [4][9]. - The two companies have collaborated on significant marketing initiatives, including sponsoring the popular variety show "Flowers and Youth: Together Season" and creating the "Ace Super Product Day" marketing IP [4][9]. Group 3: Future Collaboration Focus - In 2026, the partnership will focus on four key areas: products, marketing, user experience, and mechanisms, with increased resource investment to achieve new growth breakthroughs [4][9]. - Future collaboration will enhance supply chain efficiency, user health management, and data-driven innovation, leveraging JD Health's integrated sales and supply chain capabilities [5][9]. Group 4: Strategic Goals and Vision - JD Health aims to provide more precise and personalized health solutions for families, supporting the long-term sustainable development of H&H Group's diverse nutrition product lines [5][9]. - H&H Group's CEO expressed that JD Health is one of their most important partners in the Chinese market, emphasizing the integration of global quality nutrition resources with JD Health's digital technology and user insights [5][9]. - JD Health's CEO stated the intention to deepen strategic collaboration across all channels and links, aiming for reliable and scientifically professional nutrition health services to reach more families [5][9].

Core Insights - Dain Pharmaceutical has launched the melatonin granules, Manlejing®, for the treatment of sleep disorders in children with neurodevelopmental disorders, marking it as the only approved melatonin medication in China for this purpose [1][2] - The introduction of Manlejing® addresses a significant health challenge, as nearly half of children with conditions like autism spectrum disorder and attention deficit hyperactivity disorder experience sleep issues that affect their overall development [1] Group 1 - Manlejing® is designed in a granule form with a sweet taste, making it easier for children to consume [1] - Clinical studies indicate that after two weeks of using Manlejing®, children's sleep onset latency is reduced by over 36 minutes, significantly alleviating difficulties in falling asleep [2] - Continuous use of Manlejing® leads to improvements in both nighttime sleep and daytime behavior, helping to reduce issues such as hyperactivity, irritability, and inappropriate language [2] Group 2 - The International Pediatric Sleep Association (IPSA) and the American Academy of Neurology (AAN) recommend that children use pharmaceutical-grade melatonin, reinforcing the credibility of Manlejing® [2] - JD Health plans to leverage its robust pharmaceutical health service ecosystem to collaborate with Dain Pharmaceutical and other renowned companies to introduce cutting-edge therapeutic drugs, aiming to provide comprehensive digital health management solutions for affected children [2]

Core Insights - The integration of digital transformation and the "Healthy China" strategy has elevated corporate health management from a traditional welfare option to a critical variable for organizational resilience and growth certainty [1] - JD Health is emerging as a core driver in the rapidly growing market, leveraging its unique advantages such as a vast customer base and comprehensive health service capabilities [1][3] - The establishment of the "2026 Billion Brand Alliance" aims to enhance collaboration and accelerate market penetration for partner brands in the corporate health sector [6] Market Dynamics - The corporate health consumption market is experiencing explosive growth driven by policy support, corporate demands, and heightened employee health awareness [1] - JD Health's enterprise business has seen significant performance, with over 800 partner brands and a notable number achieving sales in the millions [3] Strategic Development - JD Health has outlined three core development directions for 2026: solidifying product and supply chain foundations, scaling centralized procurement models, and strategically investing in corporate medical funds [1][6] - The company is transitioning from a "behind-the-scenes supplier" to a "direct service provider" in the medical fund sector, which has shown nearly 100% growth in 2025 [8][9] Service Innovation - JD Health is focusing on creating a comprehensive health service ecosystem that integrates various health management scenarios, including emergency response and chronic disease management [4][5] - The company is enhancing its digital capabilities through AI tools to provide precise service matching and improve the overall employee health management experience [4][6] Competitive Advantages - JD Health's competitive edge lies in its robust supply chain, strong service capabilities, and deep integration of digital tools, which collectively enhance its market position [3][4] - The company is committed to transforming employee health management into a core driver of organizational productivity and high-quality development [2][10]